Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded by stock analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday.
Other analysts have also issued reports about the company. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday, October 17th. UBS Group reduced their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, October 12th. Instinet assumed coverage on Sucampo Pharmaceuticals in a research report on Tuesday, December 19th. They issued a “buy” rating and a $43.00 price target for the company. Nomura assumed coverage on Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a “buy” rating and a $43.00 price target for the company. Finally, Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 7th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $20.25.
Shares of Sucampo Pharmaceuticals (SCMP) opened at $17.98 on Friday. The stock has a market capitalization of $846.67, a price-to-earnings ratio of 12.29, a price-to-earnings-growth ratio of 5.04 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $18.75.
In related news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. 4.13% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of SCMP. Point72 Asset Management L.P. purchased a new position in Sucampo Pharmaceuticals during the third quarter worth about $21,989,000. Prudential Financial Inc. grew its position in Sucampo Pharmaceuticals by 871.6% during the third quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after buying an additional 368,090 shares in the last quarter. Gabelli Funds LLC purchased a new position in Sucampo Pharmaceuticals during the fourth quarter worth about $5,403,000. Engineers Gate Manager LP grew its position in Sucampo Pharmaceuticals by 367.5% during the fourth quarter. Engineers Gate Manager LP now owns 261,931 shares of the biopharmaceutical company’s stock worth $4,702,000 after buying an additional 205,901 shares in the last quarter. Finally, Longfellow Investment Management Co. LLC purchased a new position in Sucampo Pharmaceuticals during the fourth quarter worth about $3,590,000. Institutional investors and hedge funds own 65.01% of the company’s stock.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.